The increasing focus on biomarker discovery and toxicogenomics, along with the increasing interest in outsourcing services, is expected to offer significant growth opportunities for the players operating in the global RNA analysis/transcriptomics market. On the other hand, the requirement of high capital investments and data management issues are expected to restrain the growth of this market to a certain extent.
The growth of this market is majorly driven by the increasing demand for personalized medicine, increasing pharmaceutical and biotechnology R&D expenditure and government funding for omics, and the increasing applications of RNA sequencing in the transcriptomics market.
Personalized medicine, which has become a core area of research in the healthcare industry, has entered mainstream clinical practice and is changing how many diseases are identified, classified, and treated.
These advancements are particularly evident in the area of oncology. According to the Personalized Medicine Coalition report (2017), the number of personalized drugs, treatments, and diagnostic products has increased since 2006, and this trend is expected to continue in the coming years.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=240344576
The microarray technology used in transcriptomic analysis offers the promise of widespread study of diseases at the genomic level. It also aids in developing novel clinical biomarkers, identifying novel molecular abnormalities, and investigating drug efficacy.
Moreover, RNA sequencing data from transcriptomics studies have low genome coverage and high amplification bias, which makes data analysis extremely challenging, especially without effective bioinformatics tools. Many existing tools developed for bulk cell sequencing have not been effective in the analysis of transcriptomics data.
The PCR segment accounted for the largest share of the RNA analysis/transcriptomics market in 2019. PCR is the most suitable technique for interrogating a relatively small number of transcripts in a large set of samples. The increasing investments being made in the life science research and omics fields are also driving the adoption of the PCR technology for clinical diagnostic.
The prominent players in this market are Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Illumina, Inc. (US), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US).
The increasing investments by governments and industries, growing biotechnology research in APAC countries, and the rising awareness about personalized therapeutics are expected to drive the growth of this regional market during the forecast period. Furthermore, the increasing focus on Asia Pacific countries due to their low-cost manufacturing advantage is expected to provide growth opportunities for manufacturers.
The increasing demand for high-quality reagents and the repeated use of media and reagents in transcriptome studies. Additionally, the growing R&D activities in the pharmaceutical industry, growing government investments in the field of life science research, and the increasing research being undertaken with integrated omics studies are contributing to the market for consumables.
Factors such as the increasing R activities and expenditure in the life science industry, increasing funding for proteomics research and drug discovery, and the growing collaboration between industries and academic institutes are the key drivers of the research antibodies market.The Research Antibodies Market is projected to reach USD 14.1 billion by 2025 from USD 10.1 billion in 2020, at a CAGR of 6.7% during the forecast period.
Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=94212793Market Segmentation:-On the basis of product, the reagents segment accounted for the largest share of the global research antibodies market (including reagents), in 2016.
This can be attributed to the fact that a large number of reagents are used in various routine assays and techniques.Based on technology, the western blotting segment accounted for the largest share of the Research Reagents Market.
Its ability to quantify as little as 0.1 nanograms of protein in a sample with high specificity makes it an indispensable tool in proteomic research; this is the key factor driving market growth.Based on application, the proteomics segment accounted for the largest share of the Research Reagents Market.
The large share of this segment is attributed to the deployment of proteomic-based approaches in biomarker detection and cancer profiling, increasing R expenditure, and availability of funds from various organizations.Based on end user, the pharmaceutical & biotechnological companies segment accounted for the largest share of the Research Antibodies and Reagents Market owing to the high uptake of research-specific antibodies in the drug discovery and development process, along with the increasing use of these research tools in the ever-developing proteomics research sector.Key Market Opportunities: - 1 High Growth Opportunities in Emerging Markets 2 Increasing Demand for Personalized Medicine and Protein Therapeutics 3 Growths in Stem Cell and Neurobiology Research 4 Increasing Focus on Biomarker DiscoveryRegional Analysis:-North America accounted for the largest share of the Research Antibodies and Reagents Market in 2016, followed by Europe.
This regional segment shows significant market growth opportunities owing to the increasing research activities in the fields of proteomics and genomics, favorable government funding initiatives, and the growing focus of stakeholders on research projects.Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=94212793Top Key Players:-The major players in the research antibodies market (including reagents) are Thermo Fisher Scientific, Inc. (U.S.), Merck Group (Germany), Abcam plc (U.K.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Cell Signaling Technology, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), GenScript (U.S.), PerkinElmer, Inc. (U.S.), Lonza (Switzerland), and BioLegend, Inc. (U.S.).
The increase in prevalence of cancer among population across the globe and the increase in biomarkers adoption in tumor profiling are factors escalating the growth of cancer tumor profiling market.Cancer is generally differentiated as uncontrolled cell growth which could be fatal.
The cell mutation leads to abnormal cell growth which affects the neighboring cells and organs.
It also helps in determining the specific therapeutics for the patient.Get Sample Copy of report Click on the link @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cancer-tumor-profiling-marketCancer Tumor Profiling Market Scope and Market SizeThe global cancer tumor profiling market is segmented on the basis of cancer type, biomarker type, technology, technique and application.
The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
On the basis of cancer type, the cancer tumor profiling market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma cancer and other cancer.On the basis of biomarker type, the cancer tumor profiling market is segmented into genomic biomarker and protein biomarker.On the basis of technology, the cancer tumor profiling market is segmented into immunoassays, next-generation sequencing, polymerase chain reaction, mass spectrometry, in-situ hybridization, microarrays and others.On the basis of technique, the cancer tumor profiling market is segmented into genomics, proteomics, metabolomics and epigenetics.On the basis of application, the cancer tumor profiling market is segmented into research, biomarker discovery, personalized medicine, clinical application, diagnostics, prognostics, screening and treatment and monitoring.Get Full Table of Contents with Charts, Figures & Tables @ https://www.databridgemarketresearch.com/toc/?dbmr=global-cancer-tumor-profiling-marketGlobal Cancer Tumor Profiling Market Country Level AnalysisGlobal cancer tumor profiling market is analyzed and market size insights and trends are provided by country, cancer type, biomarker type, technology, technique and application as referenced above.
The countries covered in the cancer tumor profiling market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.North America dominates the cancer tumor profiling market because of the increasing number of cancer/tumor patients, presence of leading players, rise in oncology research activities to novel therapy and advanced technologies and their growing adoption.
Overview: Next-generation sequencing (NGS) is the massively parallel sequencing technology that has revolutionized the biological sciences.
With its ultra-high throughput, scalability, and speed, NGS enables researchers to perform a wide variety of applications and study biological systems at a level never before possible.
Illumina, Pacific Biosciences of California, Thermo Fisher scientific and Oxford Nanopore technology offers next-generation sequencing instruments based on different technologies such as Reversible terminator sequencing, Sequencing by ligation, Single-molecule, real-time sequencing (SMRT), ion semiconductor sequencing technology and Nanopore sequencing technology respectively.
Wide range of diagnostic applications, continuous technology advancements are making it more efficient and user-friendly, but the complications associated with data storage and lack of skilled professional are some of the factors which may hamper growth to an extent.Market Analysis: The “Global Next-Generation Sequencing market” is estimated to witness a CAGR of 18.6% during the forecast period 2018–2024.
The global market is analyzed based on five segments – Technology, Products, Application, End-users and regions.For Further Details about this Market Visit The Press Release@ https://www.trendsmarketresearch.com/report/sample/9896Regional Analysis: The regions covered in the report are the North America, Europe, Asia Pacific, and Rest of the World (ROW).
Asia-Pacific region is expected to grow at high CAGR during the forecasted period due to increasing funding for healthcare research, growing patient pool, and increasing healthcare expenditure.
This report aims to provide detailed insights into the global lab automation market.
It provides valuable information on the type, procedure, application, and region in the market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1158 Key Factors Driving Market Growth: The Increasing spending on pharmaceutical R, growing food safety concerns, standardization of workflows, stringent regulatory control in the healthcare industry are fueling the growth of the market.
Moreover, high demand in the emerging nation and the growth of the pharmaceutical and biotechnology industries are some of the other major factors driving the growth of this market.
Owing to the easy integration with both existing and upcoming systems are favorable options for customers looking to introduce automation in their labs.
Owing to an increase in the number of tests carried out in pharmaceutical labs for screening compounds, optimizing leads, determining drug properties with absorption, distribution, metabolism, and excretion (ADME), and toxicity has favored the argument for automation.
Real Time PCR (QPCR) Market OverviewGlobal Real Time PCR (qPCR) market is valued at US$ 4,154.9 Mn in 2018 and is expected to grow at a CAGR of 8.8% to reach US$ 8,890.5 Mn in 2030.
Limited supply of real time PCR (qPCR) testing kits in various countries is leading healthcare organizations to search for innovative testing solutions.
In real time PCR (qPCR) testing, RNA samples from a patients are utilized for testing through polymerase chain reaction (PCR) for understanding the presence of virus SARS-CoV-2.
Virus SARS-CoV-2 is responsible for COVID-19.Access Full Report Details and Order this Premium Report @ https://www.absolutemarketsinsights.com/reports/Real-Time-PCR-qPCR-Market-2019-2030-555Top Key Venders of Market:Some of the players operating in the Real Time PCR (qPCR) market are ABL SA Group, Agilent Technologies, Inc., Analytik Jena AG, BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Fluidigm Corporation, Lumex Instruments, Primerdesign Ltd, QIAGEN, Takara Bio Inc., Thermo Fisher Scientific, TOYOBO.inc., and Vela Diagnostics amongst others.Key Findings of the Report:The use of Real Time PCR (qPCR) (qPCR) for virus and bacterial analysis is expected to grow significantly over the forecast period.
The increasing adoption of the method for testing with respect to coronavirus (COVID-19) is aiding the growth of the segment in the global market.The usage of Real Time PCR (qPCR) is observed to be at the highest in healthcare sector through hospitals and clinics across various regions.
The increasing number of cases for testing of coronavirus (COVID-19) across various regions is aiding the growth of the segment in the market.As far as geography is concerned, the market for Real Time PCR (qPCR) is expected to grow at a faster rate in the North America region.
Lichen nitidus treatment market is a rare skin disease which occurs as skin-colored, tiny bumps on the surface of the skin.
It is usually seen in children and young adults.
It rarely causes discomfort and usually goes without treatment.
Doctors usually use magnifying glass to look at the infected skin to examine the symptoms.
It can occur in areas such as forearms, abdomen, chest, back of hand and many more.lichen nitidus treatment market is registering a substantial CAGR of 8.9% in the forecast period of 2019-2026.
This rise in the market can be attributed to the rising prevalence of skin related diseases across the world which is the major factor driving the global market.This Lichen Nitidus Treatment Market research report intensely analyses the potential of the market with respect to current scenario and the future prospects by considering several industry aspects of Cardinal Health industry.
